Viatris Inc. is a global pharmaceutical company formed in November 2020 through the combination of Pfizer's Upjohn business and Mylan. It develops, manufactures, and markets generic and branded medicines, complex generics, biosimilars, and over-the-counter products across major therapeutic areas including cardiovascular, central nervous system, diabetes, dermatology, ophthalmology, and gastroenterology. Its portfolio includes well-known branded medicines such as Lipitor, Norvasc, Lyrica, and Viagra, alongside a broad range of generic equivalents. Viatris sells to wholesalers, pharmacies, hospitals, governments, and other healthcare providers in more than 165 countries, with significant operations in North America, Europe, and emerging markets. Revenue comes primarily from pharmaceutical product sales, split between generics and its legacy branded portfolio, supplemented by contract manufacturing and active pharmaceutical ingredient supply through its Viatris segment. The company also operates manufacturing and research facilities worldwide.

Piotroski F-Score

Beneish M-Score

Operating Margin %

Dividend Payout Ratio

PB Ratio

Revenue per Share

Price

PS Ratio

ROIC vs WACC

Dividend Yield %

Altman Z-Score